TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The SIMPLIFIED trial found that high-dose vitamin D3 did not significantly improve overall survival or several other outcomes among adults receiving dialysis. Signals in male and non-white participants, and a nominal cardiovascular finding, are exploratory and need further study.
High-dose vitamin D3 did not significantly improve overall survival among adults receiving dialysis for end-stage kidney disease in the SIMPLIFIED trial, according to results presented by Rona Smith of the University of Cambridge at the American Society of Nephrology Kidney Week meeting. The finding challenges the idea that routine high-dose supplementation can reduce the substantial mortality burden in this group.
The pragmatic U.K. trial randomized 3,866 adults at 55 renal units to receive 60,000 international units of cholecalciferol, a form of vitamin D3, every two weeks or standard care without trial supplementation. Median follow-up was 7.5 years. Researchers recorded 1,817 deaths during the trial.
Overall survival did not differ significantly between the groups: the conditional hazard ratio was 0.95 (95% confidence interval 0.86 to 1.04; P=0.26). The researchers also reported no significant differences in the listed secondary outcomes, which included fatal and nonfatal cardiovascular events, infections, fractures and malignancy. Sensitivity analyses accounting for transplantation, COVID-19 infection and stopping treatment did not change the primary result.
The supplement raised vitamin D levels in a first group of 206 participants assessed after four months: median plasma 25-hydroxyvitamin D was 141 nmol/L in the supplementation group and 36.5 nmol/L in controls. Smith said high-dose cholecalciferol was safe and well tolerated. At least one hospital admission occurred in 69% of the intervention group and 70% of those receiving standard care.
Why Routine High-Dose Dosing Is Unsupported
The results address a clinical evidence gap for a population with high rates of vitamin D deficiency and poor long-term outcomes. Low vitamin D has been associated with mortality and other adverse outcomes in observational research, but an association does not establish that supplementation prevents those outcomes. In this randomized trial, substantially raising vitamin D levels did not translate into a statistically significant survival advantage.
That distinction matters for patients and clinicians weighing routine high-dose treatment. The trial findings do not show that vitamin D is never appropriate for an individual patient or that deficiency should be ignored. They indicate that this particular high-dose schedule did not improve survival across the overall study population. Decisions about testing and replacement should be made with a qualified clinician, based on a patient’s circumstances and applicable guidance.
Products Worth Considering
Bowflex PR1000 Home Gym
OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG
Levoit Eleva 300X HEPA Air Purifier for Home and Bedroom
As an affiliate, we earn on qualifying purchases.
How SIMPLIFIED Tested Supplementation
Participants had a median age of 65; 68% were men, 80% were white and 40% had diabetes. Nearly all, 94%, received in-center hemodialysis, and the median time on dialysis at enrollment was 2.25 years. The trial excluded people with an expected life expectancy under six months, recent use of more than 1,000 IU of cholecalciferol per day, or persistent hypercalcemia.
Smith said Kidney Disease: Improving Global Outcomes guidelines suggest measuring 25-hydroxyvitamin D in people with stage 3-5 chronic kidney disease, including those on dialysis, and replacing it when levels are deficient. She noted the guidelines recognize the evidence grade is low. SIMPLIFIED tested whether a fixed high-dose regimen could address that uncertainty. Apart from an in-person baseline assessment, follow-up was remote, and outcomes were drawn from routinely collected electronic health records.
Subgroup Signals Need Confirmation
Prespecified subgroup analyses suggested a possible benefit among men and participants of non-white ethnicity. Smith said the study was not powered to establish effects in these groups, so the results are hypothesis-generating rather than definitive. She noted that non-white participants tend to have lower baseline vitamin D levels and said the subgroup may merit further research.
The trial also recorded a nominal reduction in overall major adverse cardiovascular events (hazard ratio 0.88, 95% CI 0.78 to 0.99; P=0.03), driven mainly by fewer peripheral arterial disease events (hazard ratio 0.80, 95% CI 0.65 to 0.99; P=0.04). Smith cautioned that the study was not powered to confirm findings for these individual endpoints. The available report does not establish whether these signals will hold in other studies or identify which patients, if any, might benefit.
Further Trials Must Test Signals
The overall result does not support routine use of this high-dose schedule to improve survival in dialysis patients. The next research question is whether the subgroup and cardiovascular signals can be reproduced in studies designed to test them directly. Smith said future work could examine participants of non-white ethnicity, but no specific follow-up trial or timeline was provided in the report. Until further evidence is available, those exploratory results should not be treated as established treatment benefits.
Key Questions
Did high-dose vitamin D improve survival in the trial?
No. The SIMPLIFIED trial found no statistically significant difference in overall survival between participants assigned high-dose cholecalciferol and those receiving standard care.
What dose did participants receive?
The intervention was 60,000 IU of cholecalciferol every two weeks. The trial compared that regimen with standard care without the trial supplement.
Did the study find any possible benefits?
Exploratory analyses suggested possible benefit in male and non-white participants, alongside a nominal reduction in major cardiovascular events. The researchers cautioned that these findings were not definitive and need confirmation.
Does this mean dialysis patients should never take vitamin D?
No. The result concerns one high-dose schedule and its effect on trial outcomes; it does not determine whether an individual with vitamin D deficiency should receive replacement. Patients should discuss testing and treatment with a qualified clinician.
Source: medpagetoday.com
